Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Other Non-current Assets
Long-term assets not reported separately.
Alumis Inc. Common StockNASDAQ: ALMS
Other Non-current Assets · Q2 FY2026 · quarter ended Jun 2026
Other non-current assets falls 14.9% from a year ago
Other non-current assets stood at $3.28M at the end of Q2 FY2026, down 14.9% from a year earlier and down 94.0% from the prior quarter. Over 3 fiscal years it compounded at +88.2% a year.
Context
- Other non-current assets amounted to 0.6% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -14.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.59M USD
- Year-over-year change
- +581.8%
- 3-year CAGR
- +88.2%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.59M | +581.8% |
| FY2024 | 2024-12-31 | 1.11M | +8.0% |
| FY2023 | 2023-12-31 | 1.03M | -9.4% |
| FY2022 | 2022-12-31 | 1.14M | — |
Other Non-current Assets vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -14.9% is the 5th highest of 7, against a peer median of +19.8%.
- Other non-current assets amounts to 0.6% of total assets for ALMS, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $3.28M USD | -14.9% | +88.2% | 0.6% |
| Mar 2026 | $2.36M USD | +55.5% | +43.9% | 0.5% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €2.21M EUR | — | — | 1.3% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $919K USD | +93.9% | +21.1% | 0.9% |
| Mar 2026 | $256K USD | +0.0% | +0.0% | 0.1% | |
| Mar 2026 | $231K USD | -92.7% | — | 0.1% | |
| Mar 2026 | $183K USD | +39.7% | +17.0% | 0.2% | |
| Mar 2026 | €139.34K EUR | -27.0% | -21.1% | 0.3% | |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +19.8% | +17.0% | 0.2% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.